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Notch signaling regulates myogenic regenerative
capacity of murine and human mesoangioblasts
M Quattrocelli1, D Costamagna1, G Giacomazzi1, J Camps1 and M Sampaolesi*,1,2
Somatic stem cells hold attractive potential for the treatment of muscular dystrophies (MDs). Mesoangioblasts (MABs) constitute a
myogenic subset of muscle pericytes and have been shown to efficiently regenerate dystrophic muscles in mice and dogs. In
addition, HLA-matched MABs are currently being tested in a phase 1 clinical study on Duchenne MD patients (EudraCT #2011-
000176-33). Many reports indicate that the Notch pathway regulates muscle regeneration and satellite cell commitment. However,
little is known about Notch-mediated effects on other resident myogenic cells. To possibly potentiate MAB-driven regeneration
in vivo, we asked whether Notch signaling played a pivotal role in regulating MAB myogenic capacity. Through different
approaches of loss- and gain-of-function in murine and human MABs, we determined that the interplay between Delta-like ligand 1
(Dll1)-activated Notch1 and Mef2C supports MAB commitment in vitro and ameliorates engraftment and functional outcome after
intra-arterial delivery in dystrophic mice. Furthermore, using a transgenic mouse model of conditional Dll1 deletion, we
demonstrated that Dll1 ablation, either on the injected cells, or on the receiving muscle fibers, impairs MAB regenerative potential.
Our data corroborate the perspective of advanced combinations of cell therapy and signaling tuning to enhance therapeutic
efficaciousness of somatic stem cells.
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Notch signaling consists of a conserved pathway, triggered by
physical interaction between one ligand and one receptor,
both transmembrane proteins exposed by contacting cells.1
Notch signaling has been involved in different stages of
muscle formation2 and regeneration.3,4 The canonical signal-
ing encompasses five ligands (Dll1/3/4, Jagged1/2) and four
receptors (Notch1–4); however, the axis Dll1-Notch1 appears
consistently involved during myogenic fate specification, for
example, neural crest-driven somite maturation.5 Moreover,
murine embryos expressing a hypomorphic allele of the Notch
ligand Dll1 displayed marked impairment of skeletal muscle
formation.6 Interestingly, the Notch pathway may exert
different effects according to the cell context. Culture on
DLL1-coated plastic improved ex vivo proliferation and in vivo
engraftment of canine satellite cells.7 Expression of the active
Notch1 intracellular domain (NICD) robustly committedmurine
and rat mesenchymal stem cells toward the myogenic fate
both in vitro and in vivo.8 However, Notch-mediated effects on
the regenerative potential of non-satellite resident myogenic
cells are still unknown.
Mesoangioblasts (MABs) are non-satellite resident myo-
genic stem cells, able to circulate and regenerate dystrophic
skeletal muscles.9,10 HLA-matched MABs are currently under
phase 1 clinical study on Duchenne muscular dystrophy
patients (EudraCT #2011-000176-33). In this view, under-
standing the cell-specific effects and mechanisms of myo-
genic cues will help improving clinical translation of MAB-
based therapies in vivo. Recently, it has been shown that
Notch synergizes with Pdgf-bb to convert fetal myoblasts into
myogenic pericytes.11 However, knowledge about Notch-
triggered effects on the regenerative potency of somatic
MABs is still scant, particularly in the contexts of cell–cell
(in vitro) and fiber–cell (in vivo) contact.
Therefore, we asked whether the Dll1-Notch1 axis regulates
the myogenic potential of murine and human MABs and how to
tune this pathway to ameliorate in vivoMAB-driven regeneration.
Results
Dll1-Notch1 regulate in vitro differentiation of murine and
human MABs. For this study, we used murine12 and human
MABs,13 both isolated from somatic muscles as alkaline
phosphatase+ (AP+) cells and processed as previously
reported14 (Supplementary Figure 1). Consistently, with
antecedent reports, AP+ murine MABs do not spontaneously
undergo myogenic differentiation in vitro, unlike human AP+
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MABs9,10 (Supplementary Figure 2). We analyzed the pattern
of Notch1, Dll1 and Hes1 expression and of pathway
activation during spontaneous in vitro differentiation. Murine
MABs showed slight upregulation of Notch1 at day 3, but
progressive downregulation of Dll1 and Hes1 over time,
matching Dll1 and NICD (activated receptor) protein levels
(Figures 1a and b; Supplementary Figure 3a). Conversely,
human MABs showed early upregulation of NOTCH1, DLL1
and HES1, paralleled by increasing protein levels of DLL1
and NICD at day 3, followed by rapid decrease (Figures 1c
and d; Supplementary Figure 3a). To investigate the role of
epigenetics in the species-specific pattern of Dll1 expression,
we monitored the DNA methylation propensity along the
regulatory regions of the genomic Dll1/DLL1 locus. Interest-
ingly, Dll1 regulatory regions appeared more rapidly methy-
lated in murine than in human MABs (Figures 1e and f), being
the overall methylation propensity along the murine
sequences significantly higher at day 0 and 3 than in the
human DLL1 locus (Supplementary Figure 3b). Thus, during
spontaneous differentiation in vitro, murine MABs do not
spontaneously mature into myocytes and exhibit rapid locus
methylation and decreased expression of Dll1 at early stage,
correlating with decreased Notch1 activation. Conversely,
human MABs mature into myocytes in vitro and show
Figure 1 The axis Dll1-Notch1 regulates the in vitromyogenic potential of murine and human MABs. (a–d) Expression levels of Notch1/NOTCH1, Dll1/DLL1 and Hes1/HES1
(Notch1 activation reporter), and WB analysis of Notch1/NOTCH1, its activated form (Notch1/NICD) and Dll1/DLL1 in murine and human MABs over time during spontaneous
differentiation in vitro. Expression levels are reported in arbitrary units (AU) as fold change versus day 0. (e, f) Summary array of methylation propensity along upstream CpG
islands (one in the murine locus, two in the human), 5′-UTR and 3′-UTR of Dll1/DLL1 genomic loci in murine and human MABs at day 0, day 3 and day 5 of spontaneous
differentiation, as assayed by qPCR-based test on genomic fragments enriched in highly methylated DNA. − , unmethylated control, APC promoter; +, methylated control and
propensity reference, NBR2 promoter. (g) Immunofluorescence staining on co-cultures of C2C12 myoblasts with murine MABs transduced with lentiviral vectors carrying a GFP
tracer and scramble, or anti-Notch1, or anti-Dll1 interfering shRNAs. White arrows indicate chimeric GFP+/MyHC+ myotubes and MAB myogenic differentiation. Scramble and
scramble +γ-secretase inhibitor (gsi) conditions represent the controls of unperturbed and chemically inhibited signaling, respectively. (h) Immunofluorescence staining on
differentiated human MABs after transduction with lentiviral vectors carrying a RFP tracer and scramble, or anti-NOTCH1, or anti-DLL1 interfering shRNAs. Presence of MyHC+
mono/bi-nucleated myocytes indicate MAB myogenic differentiation. (i, j) Immunofluorescence staining to evaluate the dose-dependent effects of transient Dll1/DLL1
overexpression on the in vitro myogenic differentiation of murine and human MABs, both transduced with lentiviral vectors carrying conditional expression of the ligand under
doxycycline (doxy) control; − , 0 μg/ml, basal control; +, 0.1 μg/ml; ++, 1 μg/ml; +++, 10 μg/ml. To confirm Notch signaling involvement in the observed effect, gsi-supplemented
control conditions are also shown. To assess the myogenic contribution of murine MABs in co-culture with C2C12, GFP+ murine MABs have been used in this experiment. Data in
charts are depicted as mean± standard deviation of ≥ 3 independent experiments. Scale bars indicate 100 μm
Notch signaling and mesoangioblast potency
M Quattrocelli et al
2
Cell Death and Disease
sustained Dll1 expression and Notch1 activation at early
differentiation step.
We then investigated the effects of loss and gain of Notch
signaling on the in vitromyogenic capacity of MABs. This was
assayed in murine MABs by co-culture/fusion with C2C12
myoblasts, whereas human MABs were assayed in sponta-
neous differentiation toward myocytes. Specific knockdown of
Notch1 and Dll1 (Supplementary Figure 4a), as well as
treatment with γ-secretase inhibitor (gsi), resulted in
decreased NICD levels (Supplementary Figure 4b), and in
impairment of murine MAB fusion with myoblast-derived
myotubes, as compared with scramble control (Figure 1g).
Analogously, gsi and NOTCH1/DLL1 knockdown led to
impaired maturation of human MABs into MyHC+ myocytes
(Figure 1h). We also analyzed the involvement of other
receptors and ligands, for example, Notch2 receptor and
Jag1 ligand, in our in vitro system. Knockdown of Notch2/
NOTCH2 or Jag1/JAG1 did not significantly alter MAB
myogenic differentiation, as compared with scramble control
(Supplementary Figure 5), supporting the hypothesis that the
Dll1-Notch1 axis is pivotal in our experimental system. We
next used a lentiviral system of doxycycline-triggered Dll1/
DLL1 overexpression to evaluate the effects of gain-of-
function in the early differentiation step. After application of
doxycycline till day 3 of differentiation, Dll1/DLL1 overexpres-
sion dose-dependently increased in vitromyogenic maturation
of both murine and human MABs (Figures 1i and j). This effect
was significantly decreased in the presence of gsi
(Supplementary Figure 6), thus confirming the direct involve-
ment of Dll1-triggered Notch signaling in the early differentia-
tion step of murine and human MABs.
As additional proof of principle, we sought to apply our dose-
dependent system of transient Dll1 overexpression to a MAB
model of robust myogenic differentiation. To this purpose, we
used murine Sgcb-null MABs, previously reported as aber-
rantly and spontaneously myogenic.15,16 Transient over-
expression of Dll1 dose-dependently correlated with
increasedHes1 expression at day 3 (Figure 2a) and enhanced
myotube formation at day 7 (Figure 2b). Thus, Dll1-Notch1
signaling during the early differentiation/commitment step
sustains MAB myogenic differentiation at a later stage.
We askedwhetherMef2C andMaml1, reported interactors of
NICD in other myogenic cell models,17,18 were involved in Dll1-
dependent effects on MAB differentiation. Murine MABs
showed progressive decline of gene and protein levels of
Mef2C over time, whereas MEF2C was upregulated at days
3–5 in human MABs. Moreover, the levels of Maml1/MAML1
appeared stable over time in both murine and human MABs
(Figures 3a and d and Supplementary Figure 7a). Notably, at
day 3 of spontaneous differentiation, Mef2C and Maml1 are
only partially associated to NICD and Dll1 knockdown resulted
inmajor dissociation from the residual NICD levels. Conversely,
Dll1 overexpression led to complete Mef2C recruitment,
whereas only after combined overexpression ofDll1 andMef2C
did Maml1 appear completely associated to the NICD complex
(Figure 3e). Because Maml1 was reported as activator of
Mef2C upon dissociation fromNICD,17 we quantified the effects
ofMaml1 recruitment onMef2C activity in our cell system at day
5 of differentiation, when NICD levels are depleted in normal
conditions. Using a Mef2C-responsive luciferase system,
Mef2C transcriptional activity in murine MABs was decreased
after Dll1 knockdown and significantly increased after com-
bined overexpression of Dll1 and Mef2C (Figure 3f). We
obtained analogous data also from human MABs (Figure 3g
and h). Thus, the Dll1-Notch1 axis appears as amajor regulator
of the in vitromyogenic ability of bothmurine and humanMABs,
and Dll1-triggered signaling cooperateswith Mef2C andMaml1
in enhancing Mef2C activity at later stages.
Priming murine and human MABs for enhanced in vivo
regeneration. Subsequently, we sought to determine
whether tuning the signaling without genomic integrations
could ameliorate the in vivo regenerative potential of murine
and human MABs. We used an adenoviral-based, non-
integrative system of temporary overexpression of Dll1 or
Mef2C (Ad-Dll1 and Ad-Mef2C, respectively, Supplementary
Figure 2 Dll1 dose-dependently enhances in vitromyogenic ability of Sgcb-null cardiac MABs. (a) According to increasing concentrations of doxycycline, expression levels of
Dll1 and Hes1 are significantly upregulated at 72 h post transduction (*Po0.05; n= 6). Expression levels are reported in arbitrary units (AU) as fold change versus transduced
MABs in absence of doxycycline. Data in charts are depicted as mean± standard deviation. (b) Immunofluorescence staining at day 7 of differentiation shows enhanced in vitro
myogenic ability, following increasing concentrations of doxycycline, applied till day 3. Scale bars indicate 100 μm
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Figures 7b and c), priming the cells in vitro prior to bilateral
intra-arterial injection into dystrophic mice. After injection into
Sarcoglycanα(Sgca)-null mice, combined priming of green
fluorescent protein (GFP)+ murine MABs with Ad-Dll1 and
Ad-Mef2C resulted in enhanced levels of engraftment into
GFP+ chimeric fibers and restoration of Sgca, as shown by
immunostaining, western blotting (WB) and quantitative
polymerase chain reaction (qPCR) at 4 weeks (Figures 4a
and b and Supplementary Figure 8) and 8 weeks post
injection (data not shown). Accordingly, fibrotic scars
appeared also reduced in treated mice (Supplementary
Figure 9a). We then assessed the functional relevance of
histological and molecular data by gait analysis and treadmill
assay. In both tests, combined priming of injected MABs
significantly ameliorated the functional outcome, both at 4
(Figures 4c and d) and 8 weeks (Supplementary Figure 9b)
post injection. Moreover, combined priming did not increase
off-target engraftment, which appeared poor in all conditions
(Supplementary Figure 10 and data not shown). Comparably,
we tested the adenoviral priming system on human MABs
and assessed their in vivo myogenic potential by bilateral
intra-arterial delivery in acutely damaged muscles of Rag2-
null/γc-null immunodeficient mice.19 Similarly to murine
MABs, combined priming of human GFP+ MABs with Ad-
DLL1 and Ad-MEF2C resulted in higher levels of engraftment
(Figure 4e) and detection of human-specific DYSTROPHIN
and sarcomeric ACTININα (Figure 4f and Supplementary
Figure 11). Hence, non-integrative priming with Dll1 and
Mef2C enhances myogenic capacity and regenerative
potential of both murine and human MABs in vivo.
Analysis of Dll1 requirement using transgenic MABs and
muscles. To further examine the directionality of the ligand
presentation at the interface between the homing cell and the
host fiber, we examined MABs and muscle fibers of Dll1flx/flx;
Rosa26::iCreERT2+/− (flx) transgenic mice, allowing condi-
tional tamoxifen-driven Dll1 knockout (Supplementary Figures
12a and c). To examine the requirement of Dll1 presentation by
the homing cell, we isolated and characterized flx MABs
(Supplementary Figures 12d and e) from post-natal muscles of
the transgenic mice, as previously described.14 We then tested
their myogenic potential in vitro by fusion with C2C12-derived
myotubes, and in vivo by intra-arterial delivery into Sgca-null
mice (Figure 5a). After tamoxifen-driven Dll1 knockout, flx
GFP+ MABs showed significant impairment in the contribution
to GFP+ myotubes in vitro (Figure 5b) and to Sgca+/GFP+
fibers in vivo (Figures 5c and d and Supplementary Figures
13a and b), as compared with vehicle-treated cells. Interest-
ingly, Dll1 knockout in homing flx MABs resulted also in
significant reduction of the functional outcome at 4 and
8 weeks post injection, as assayed by gait analysis and
treadmill test (Figure 5e and Supplementary Figure 13c). To
validate our transgenic model, we also assayed flx satellite
cells, which, as expected,20 showed reduced levels of Pax7
and increased spontaneous differentiation after tamoxifen
addition (Supplementary Figures 14a and b). Subsequently,
we asked whether Dll1 presentation by the host fiber is also
Figure 3 Dll1-triggered Notch signaling in MABs interplays with Maml1 and Mef2C and results in increased Mef2C activity. (a–d) Expression and protein levels of Mef2C/
MEF2C andMaml1/MAML1 in murine and human MABs over time during spontaneous differentiation in vitro. Expression levels are reported in arbitrary units (AU) as fold change
versus day 0. (e) Results of NICD-based immunoprecipitation (IP-NICD) at day 3 of differentiation of murine MABs in control conditions (ctrl), and in conditions of Dll1 knock-down
(anti-Dll1), Dll1 overexpression (+Dll1), and combined overexpression of Dll1 and Mef2C (+Dll1/+Mef2C). Input, protein extract; IgG, mouse IgG-based IP, negative control;
unbound, unbound fraction after IP. (f) Luciferase activity assayed at day 5 of differentiation after transfection with a plasmid carrying firefly luciferase expression under the control
of a Mef2C-responsive element into murine MABs after Dll1 silencing (anti-Dll1), Dll1 overexpression (+Dll1),Mef2C overexpression (+Mef2C), and combined overexpression of
Dll1/DLL1 and Mef2C/MEF2C (+Dll1/+Mef2C). *Po0.05 versus ctrl; §Po0.05 versus +Dll1/+DLL1 and +Mef2C/MEF2C (n= 4). Depicted in (g, h) are the analogous results
obtained with human MABs. Luciferase activity levels are reported in AU as fold change of renilla-normalized values versus ctrl conditions. Control cells were transduced with
scramble and overexpression vectors and kept doxycycline-free. Data in charts are depicted as mean± standard deviation of ≥ 3 independent experiments. Scale bars indicate
100 μm
Notch signaling and mesoangioblast potency
M Quattrocelli et al
4
Cell Death and Disease
required. We therefore tested the engraftment levels of wild-
type GFP+ MABs after intra-arterial delivery into Dll1-knockout
adult flx muscles (Figure 5f). In the absence of acute damage,
tamoxifen-treated mice did not present significant alterations or
lesions in skeletal muscles, as compared with vehicle-treated
controls (Supplementary Figure 14c). In Dll1-knockout
muscles, the rate of MAB engraftment was significantly
reduced as compared with vehicle-treated controls, as shown
by immunostaining, qPCR and WB (Figures 5g and i). Thus,
Dll1 presentation by both the homing cell and the host fiber
appears a positive regulator of MAB commitment and
engraftment.
Figure 4 Combined priming with Dll1/DLL1 and Mef2C/MEF2C enhances the in vivo regenerative capacity of both murine and human MABs. (a, b) Immunofluorescence
staining on gastrocnemius muscle slides of Sgca-null mice at 4 weeks after bilateral femoral artery injection of adenoviral-primed GFP+ murine MABs. Laminin/GFP staining
(a) has been used to evaluate engraftment and Sgca/GFP staining (b) for regeneration capacity. (c, d) Functional assessment of the adenoviral-based priming on the murine
MAB-driven muscle regeneration of dystrophic muscles at 4 weeks post injection. The gait analysis (c) has been performed on the stride length of mice spontaneously walking
along a 1 m path. The treadmill assay (d) has been performed on mice running on a 10°-uphill oriented treadmill belt with 1 m/min2 acceleration on 10 m/min starting speed. Data
points depict the value of each assayed mouse, bars indicate the average values; *Po0.05 versus sham; §Po0.05 versus Ad-Dll1 and versus Ad-Mef2C (n= 6 mice/group).
(e, f) Immunofluorescence staining on gastrocnemiusmuscle slides of Rag2-null/γc-nullmice at 4 weeks after bilateral femoral artery injection of adenoviral-primed GFP+ human
MABs. Laminin/GFP staining (e) has been used to evaluate engraftment and hDYSTROPHIN (hDYS)/GFP staining (f) for regeneration capacity. Sham, vehicle-injected control
mice; +Ad-mock, MABs primed with Ad-LacZ, adenoviral-treated control cells with unperturbed Notch signaling. Scale bars indicate 100 μm
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Figure 5 Analysis of Dll1 requirement for MAB engraftment/regenerative capacity using Dll1flx/flx;Rosa26::iCreERT2+/− (flx) transgenic MABs and muscles. (a) Representative
scheme of the experiment assessing tamoxifen-driven Dll1 knockout in the homing flx MABs, using the vehicle-treated cells as control. (b) Immunofluorescence staining on co-cultures
of C2C12 myoblasts with GFP+ flx MABs after Dll1 knockout. White arrows indicate chimeric MyHC+ myotubes and MAB myogenic differentiation. (c) Immunofluorescence staining on
gastrocnemius muscle slides to evaluate the regenerative capacity of Dll1-knockout GFP+ flx MABs at 8 weeks after intra-arterial injection into Sgca-null mice. (d) qPCR-based
quantification of engraftment (GFP) and regeneration (Sgca) into the tibialis anterior muscles at 8 weeks post injection; *Po0.05 versus vehicle-treated flx MABs (n= 5 mice/group).
(e) Functional assessment of conditionalDll1 knockout onMAB-driven regeneration of dystrophic muscles at 8 weeks after bilateral injection, by means of gait analysis (stride length) and
treadmill assay (running time, distance). Data points depict the value of each assayed mouse, bars indicate the average values; *Po0.05 versus vehicle-treated flx MABs (n= 5 mice/
group). (f) Representative scheme of the experiment assessing tamoxifen-driven Dll1 depletion in the flx muscles, using the vehicle-treated mice as control. (g) Immunofluorescence
staining on gastrocnemiusmuscle slides to evaluate the engraftment ability of homing GFP+ MABs into Dll1-knockout muscles at 4 weeks after intra-arterial injection. (h, i) Expression
and protein level analyses of GFP to quantify reduced homing ability of MABs into tibialis anterior fibers after conditional Dll1 knockout at 4 weeks post injection; *P40.05 (n= 3 mice/
group). Expression and protein levels in (d, h, i) are reported in arbitrary units (AU) as fold change versus vehicle-treated mice. Scale bars indicate 100 μm
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Discussion
Taken altogether, our data suggest that Dll1-triggered Notch1
activation plays a pivotal role in the myogenic commitment of
post-natal murine and human MABs. The difference in Dll1
epigenetic/transcriptional regulation and in Notch1 activation
during the early in vitro differentiation step could account, at
least partially, for the intrinsic difference in spontaneous in vitro
myogenic capacity between murine and human MABs. More-
over, Dll1-triggered positive influence on MAB differentiation
seems confirmed in the proof of principle ofDll1 overexpression
with the aberrantly myogenic Sgcb-null MABs. The aforemen-
tioned observations, in combination with the IP and luciferase
analyses at days 3 and 5 of differentiation, suggest a time-
dependent threshold effect of Dll1-activatedNICD interplaywith
Mef2C and Maml1 (Figure 6a). According to this hypothetical
model, in the absence of Dll1-presenting myoblasts, murine
MABs exhibit low levels of Dll1 and Mef2C at early differentia-
tion stage and, therefore, Mef2C activity at later stages is likely
insufficient to corroborate further progression. Differently,
human MABs present sufficient levels of DLL1 and MEF2C to
trigger MEF2C activity and myocyte maturation at later stage.
Furthermore, in both murine and human MABs, transient
overexpression of Dll1/DLL1 and Mef2C/MEF2C during the
early stage supposedly saturates complex formation and
correlates with enhanced myogenic capacity.
This in vitro model is reinforced by our adenoviral-based
system of MAB priming prior to injection. Adenoviruses do not
integrate in the genome21 of the engrafting MABs, still
promoting the overexpression pulse of the transgenes and
enhancing the commitment. Once transduced cells are
engrafted, the vector is likely diluted in the fibers, discontinuing
the signaling and ameliorating the regeneration outcome of
MABs in targeted muscles.
The directionality of Dll1 requirement for MAB homing and
differentiation in vivo constitutes an interesting question,
considering that Notch signals have been directly linked to
the niche engraftment by satellite cells.22 We addressed this
point by means of a transgenic system of conditional Dll1
deletion. Together with the data previously discussed, the
results obtained from flx MABs and flx muscles suggest a
potential, yet incomplete, model of the basal role of Notch on
MAB engraftment and differentiation in vivo (Figure 6b).
According to this model, Notch1 activation in the homing
MABs by Dll1-exposing cells or fibers may result in NICD-
mediated recruitment of Mef2C and Maml1. Once engrafted in
the fiber, potentially also through Dll1-mediated interactions,
NICD levels would decrease in the absence of receptor
stimulation and Mef2C would then exert its transcriptional
activity, promoting the expression of mid-late myogenic
factors. Noteworthy, this model might also point to Notch-
based recruitment of MABs by Dll1-exposing activated
satellite cells23 in the context of muscle injury.
Our study cannot exclude the contribution of other ligands or
receptors of the Notch family, probably accounting for the
remaining engraftment of Dll1-knockout MABs or in Dll1-
depleted muscles. However, other interactions appeared less
significant than the Dll1-Notch1 axis in our experimental setup,
considering that knockdown ofNotch2/NOTCH2 or Jag1/JAG1
did not impair the myogenic ability of murine and humanMABs
in vitro. Furthermore, our in vivo data indicate that ligand-based
tuning of theNotch pathway and its interactorsmay constitute a
feasible integration-free strategy to potentiate the outcome of
intra-arterial MAB therapy, possibly in combination with
approaches to ameliorate microcirculation in dystrophic
muscles.24 To potentially accelerate clinical translation of such
approaches, it will be fundamental to MAB-specifically assess
how the Notch pathway is involved in the interaction with other
resident cell types and how it intertwines with other cascades,
such as Wnt and Bone morphogenetic protein pathways.
Figure 6 Hypothetical models of Notch-based tuning of MAB myogenic
differentiation. (a) The intrinsic difference in the levels of Dll1-triggered Notch1
activation and of Mef2C could explain, at least partially, the difference in spontaneous
myogenic capability between murine and human MABs in our experimental system.
According to this hypothesis, murine MABs present low levels of Dll1-triggered
signaling and of Mef2C during the commitment stage. At a later step of differentiation,
once NICD is removed from the complex, Mef2C activity levels are therefore minimal.
Human MABs present intrinsically higher levels of DLL1 and MEF2C in vitro. As a
consequence, murine MABs fail to spontaneously produce mature myocytes in vitro,
whereas human MABs differentiate, although with low efficiency, spontaneously.
Transient overexpression of Dll1/DLL1 and Mef2C/MEF2C during the commitment
stage induces complete recruitment of Mef2C/MEF2C and Maml1/MAML1 by NICD,
thereby reinforcing Mef2C activity and myogenic capability of both murine and human
MABs, as observed in vivo. (b) Representative scheme of the hypothetical model
regarding Dll1 involvement during the commitment-differentiation transition of MABs
in vivo, according to our experimental setup with transgenic MABs and muscles.
Dll1-Notch1 interactions between the dystrophic fiber and the homing MABs trigger
their commitment and engraftment, plausibly through Maml1/Mef2C interplay. After
engraftment, the signaling is discontinued, NICD removed and the engrafted MABs
activate the myogenic program, likely through sustained levels of Mef2C activity
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Materials and Methods
Cell culture, isolation and differentiation. Murine AP+ MABs12 (n= 3
clones from 3 individuals; p10-20) were cultured on collagen (Sigma-Aldrich,
St. Louis, MO, USA)-coated plastic vessels (Nunc, Penfield, NY, USA) in DMEM20%
medium (DMEM 4.5 g/l glucose, supplemented with 20% heat-inactivated fetal
bovine serum, 1% Pen-Strep, 1% L-glutamine, 1% sodium pyruvate, 1% non-
essential aminoacids, 0.2% 2-mercaptoethanol; all reagents by Life Technologies,
Carlsbad, CA, USA) at 37 °C/5%O2. Human AP
+ MABs (n= 3 clones from 3
individuals; p8-15) were isolated by fluorescence-activated cell sorting (FACS) from
human MAB populations13 by AP-PE antibody (R&D Systems, Minneapolis,
MN, USA; 2 μl/105 cells) at FACS Aria III (BD, Franklin Lakes, NJ, USA). Human
AP+ MABs were cultured on collagen (Sigma-Aldrich)-coated plastic vessels (Nunc)
in IMDM10% medium (IMDM medium, supplemented with 10% heat-inactivated
fetal bovine serum, 1% Pen-Strep, 1% L-glutamine, 1% sodium pyruvate, 1% non-
essential aminoacids, 0.2% 2-mercaptoethanol, 5 ng/ml human FGF2 (Peprotech,
Rocky Hill, NJ, USA)) at 37 °C/5%O2. Antigen profiling was performed with APC-
conjugated antibodies (eBioscience, San Diego, CA, USA), following antibody
specifications and appropriate isotypes, at FACS Canto (BD), then data were
charted by FlowJo software (Tree Star, Ashland, OR, USA). AP enzymatic staining
was performed incubating for 30 min at 37 °C 2% PFA-fixed cells with SigmaFast
BCIP-NBT (Sigma-Aldrich) tablets dissolved in distilled water. Spontaneous
differentiation was performed on collagen-coated vessels in DMEM2% medium
(DMEM 4.5 g/l glucose, supplemented with 2% heat-inactivated horse serum, 1%
Pen-Strep, 1% L-glutamine) at 37 °C/5%O2. C2C12 myoblasts (p5-12) were cultured
in DMEM10% medium (DMEM 4.5 g/l glucose, supplemented with 10% heat-
inactivated fetal bovine serum, 1% Pen-Strep, 1% L-glutamine, 1% sodium
pyruvate) on plastic vessels (Corning, Corning, NY, USA) at 37 °C/5%O2.
Differentiation in co-culture was performed seeding C2C12 myoblasts with MABs
at 1 : 1 ratio, then applying DMEM2% medium after 24 h. GFP+ MABs were
obtained by integration of a GFP-bearing transposon, as previously described.12
WB, IP, qPCR and immunofluorescence/histological staining
analyses. WB analyses were performed on 50 μg starting protein extracts,
previously obtained homogenizing cells or tissues in RIPA buffer supplemented with
1% PMSF 1 mM, 1% sodium fluoride 10 mM, 1% protease inhibitor cocktail, 1%
sodium orthovanadate 0.5 mM (all reagents by Sigma-Aldrich). Gels were
polymerized with 30% acrylamide (Sigma-Aldrich) according to assayed protein
size (8% for MyHC; 10% for Dll1, NICD, Maml1; 12% for Gapdh, Mef2C, GFP) and
electrophoresis/transfer/detection was performed on gels in parallel when assaying
the same samples for multiple proteins. Incubation with primary antibody was
performed in 5% skim milk TBS-T overnight at 4 °C, whereas HRP-conjugated
secondary antibodies (1 : 5000, Santa Cruz, Dallas, TX, USA) were applied for 1 h
at room temperature. Bands were revealed after 15 min incubation with SuperSignal
Dura Chemiluminescence substrate (Thermo Scientific, Waltham, MA, USA) and
acquired at GelDoc setup (Bio-Rad, Hercules, CA, USA). Quantitation was
performed on gels loaded and blotted in parallel. Densitometric values of protein
bands were quantitated through QuantityOne software (Bio-Rad), then normalized
versus background noise and averaged values of the related Gapdh/GAPDH
internal control bands. Primary antibodies, dilutions; mouse anti-MyHC (Develop-
mental Studies Hybridoma Bank, Iowa, IA, USA; clone MF20), 1 : 10; rabbit anti-Dll1
(Cell Signaling, Beverly, MA, USA), 1 : 500; rabbit anti-Notch1 (Abcam, Cambridge,
UK), 1 : 500; rabbit anti-NICD (Abcam), 1 : 500; rabbit anti-Maml1 (Millipore,
Billerica, MA, USA), 1 : 500; rabbit anti-Gapdh (Sigma-Aldrich), 1 : 1000; rabbit
anti-Mef2C (LifeSpan Biosciences, Providence, RI, USA), 1 : 500; rabbit anti-GFP
(Life Technologies), 1 : 300.
IP was performed on 100 μg protein extracts, previously obtained homogenizing
cells in IP buffer (Tris-HCl pH 8 50 mM, NaCl 150 mM, 1% NP40, 0.5% sodium
deoxycolate, 1% PMSF 1 mM, 1% sodium fluoride 10 mM, 1% protease inhibitor
cocktail, 1% sodium orthovanadate 0.5 mM (all reagents by Sigma-Aldrich)).
Immunoprecipitation was performed by overnight incubation with 0.5 μg/reaction
mouse anti-NICD (Abcam) in a total volume of 500 μl IP buffer, while rotating at 4 °C.
Bound fraction was precipitated by proteinG-sepharose beads (GE Healthcare,
Cleveland, OH, USA) and separated from the unbound. Query proteins were then
assayed on parallel membranes by rabbit primary antibodies.
For qPCR analyses, RNA was isolated through RNA mini kit, removing gDNA traces
by Turbo DNase. One microgram RNA was reverse-transcribed by means of
SuperScript III kit and qPCR was performed in 384-well plates (10 μl final volume;
thermal profile, 95 °C 15′′ − 60 °C 45′′ (×50); ViiA 7 qPCR plate reader), using
Platinum Sybr Green Mix, 1 μl 1 : 5 diluted cDNA and 100 nM primers (all kits, reagents
and plate reader by Life Technologies). Pgk/PGK was used as internal normalizer. The
list of primers can be found in the Supplementary Materials and Methods.
Immunofluorescence staining was performed on PFA-fixed cells or cross-sectional
10 μm-thick muscle slices, obtained by cryoembedding muscles in Tissue-Tek OCT
(Sakura, Alphen aan den Rijn, The Netherlands) and cutting at CryoStar NX70
(Thermo Scientific) cryostat (−16 °C sample,− 22 °C blade). Incubation with primary
antibodies was performed in PBS supplemented with 5% BSA overnight at 4 °C,
whereas AlexaFluor-conjugated secondary antibodies (1 : 500, Life Technologies)
were applied for 1 h at room temperature. Nuclei were counterstained with 10 μg/ml
Hoechst (Sigma-Aldrich). Images were acquired at Eclipse Ti (Nikon, Tokyo, Japan)
fluorescence inverted microscope, using NIS Elements AR 4.11.01 (Nikon) software
with background ROI calibration optimized on isotype controls. Primary antibodies,
dilutions; goat anti-GFP (Abcam), 1 : 500; rabbit anti-RFP (Bio-Connect, Huissen,
The Netherlands), 1 : 200; mouse anti-MyHC (DSHB, clone MF20), 1 : 3; rabbit anti-
laminin (Sigma-Aldrich), 1 : 300; mouse anti-Sgca (Leica Biosystems, Nussloch,
Germany), 1 : 100; mouse anti-human DYSTROPHIN (Leica Biosystems, clone
Dys3), 1 : 100; rabbit anti-human sarcomeric ACTININα (Abcam), 1 : 250. Masson’s
trichromic staining was conducted on 5 μm-thick cross-sectional paraffin-embedded
muscle slices by means of staining kit (Sigma-Aldrich) according to manufacturer’s
instructions.
DNA methylation assay. CpG islands were defined by submitting the 10 kb
gDNA sequence upstream of the transcription start to CpG island searcher (http://
cpgislands.usc.edu; lower limits, CpG%= 55, ObsCpG/ExpCpG= 0.65, length=
500, distance= 100). CpG island in murine Dll1 locus, − 4257 to − 3258 bp from
transcription start. CpG islands in human DLL1 locus, − 5909 to − 3112 bp and
− 503 to − 0 bp from transcription start. gDNA was isolated from 106 cells in
proliferative conditions by means of genomic DNA Mini kit (Life Technologies) and
1 μg gDNA was randomly fragmented into fragments of 200–300 bp in 50 μl TE
buffer in Bioruptor sonication bath (Diagenode, Lieg̀e, Belgium) at 4 °C for 15 cycles
(30′′ sonication/30′′ rest) at high intensity. Sheared gDNA (200 ng) was then
enriched for fragments containing ≥ 5 me-CpGs using MethylCollector Ultra kit
(Active Motif, Carlsbad, CA, USA; low salt conditions) and purified via MinElute
Reaction CleanUp kit (Qiagen, Venlo, The Netherlands). Purified DNA was then
assayed for specific amplification of sequential fragments of regulatory regions
through Sybr green-based qPCR, using APC promoter (negative control,
unmethylated) and NBR2 promoter (positive control, methylated) as standards for
relative quantification of the methylation propensity of the single fragments. The list
of primers can be found in the Supplementary Materials and Methods.
Knockdown, overexpression and luciferase reporter vectors. For
knockdown of Dll1/DLL1 and Notch1/NOTCH1, specific shRNA-mimicking
oligonucleotides were PCR-amplified and cloned at the 3′ of the fluorescent tracer
into pGIPZ (efficient in murine MABs; reporter, GFP) or pTRIPZ (efficient in human
MABs; reporter, RFP) backbones (Open Biosystems, Huntsville, AL, USA). Vectors
carrying the scramble shRNA control were purchased. Knockdown vectors were
then used to produce lentiviral particles in 293T cells, using 2nd generation
packaging plasmids. At 24 h after application of the viral supernatant, transduced
MABs were sorted for the tracer and then plated for knockdown efficiency check
and for differentiation. MABs pre-treated for 48 h with medium supplemented with
1 : 500 γ-secretase inhibitor X (Millipore) were also then incorporated in the
differentiation experiment as control of chemical inhibition of the signaling. The list of
oligonucleotides can be found in the Supplementary Materials and Methods.
For doxycycline-driven overexpression of Dll1/DLL1 and Mef2C/MEF2C, full-
length cDNAs were purchased as in between recombining sequences compatible for
Gateway system (Genecopoeia, Rockville, MD, USA) or cloned into pENTR-11
shuttle vector (Life Technologies) from non-compatible plasmids (Open Biosystems).
cDNA sequences were then recombined into pLOVE lentiviral backbone using LR
Clonase II kit (Life Technologies), according to manufacturer’s instructions. Lentiviral
particles were produced in 293T cells, using 3rd generation packaging plasmids (5 ml
viral suspension/75 cm2 293T cells). Two milliliters of viral suspension were used to
transduce 5 × 105 cells. Twenty-four hours after transduction, doxycycline was added
for 72 h according to the different concentrations, and then removed during the
second part of differentiation. In case of gsi-treated control, gsi was added in
combination with the doxycycline. Doxycycline-driven overexpression of Dll1/DLL1
and Mef2C/MEF2C has been used for all in vitro experiments reported in Figures
1,2,3 and related Supplementary Figures.
Luciferase activity was monitored by transfecting transduced cells with RSRF-luc-
2wt25 (Addgene, Cambridge, MA, USA) and renilla luciferase plasmids by means of
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Effectene (Qiagen). Luciferase activity was quantified at day 5 of in vitro spontaneous
differentiation, normalizing firefly luciferase activity to renilla luciferase read per sample
(Dual Reporter Luciferase assay kit by Promega, Madison, WI, USA) at EG&G
microplate luminometer LB96V (Berthold, Wildbad, Germany).
For the adenoviral-based strategy, cDNAs in pENTR-11 shuttle vector were
recombined, as mentioned before, into pAd-CMV-V5-DEST, whereas pAd-CMV-V5-
GW-lacZ was used as Ad-mock control (both vectors by Life Technologies).
Adenoviral particles were produced by transfecting PacI-linearized pAd vectors into
25 cm2 293A cells (final volume= 2 ml). Upon 100% mortality, I supernatant was
used to transduce 150 cm2 293A cells (final volume= 10 ml). Upon 100% mortality, II
supernatant was frozen in 2-ml aliquots and stored at − 80 °C. One vial was used to
transduce 5 × 105 proliferating MABs and, after 48 h, cells were carefully washed,
collected and resuspended in the appropriate number/volume conditions for injection.
In vivo experiments and evaluation of the functional outcome. All
animal protocols were conducted in compliance with Ethical Committee Guidelines
of KU Leuven (project 095/2012) and Belgian legislation. Sgca-null (C57/Bl6
background) dystrophic mice (6-months old) were generated by the group of Prof.
K.P. Campbell (University of Iowa, IA, USA).26 Rag2-null/γc-null immunodeficient
mice (2-months old) were provided by the group of C. Verfaillie (KU Leuven,
Belgium). Animals were anesthetized with isofluorane. Bilateral intra-femoral artery
injection was performed with 2.5 × 105 cells/50 μl saline solution supplemented with
1 : 10000 heparin (LEO Pharma, Ballerup, Denmark)/femoral artery, using 32-gauge
needles under STEMI SV11 stereomicroscope (Zeiss, Oberkochen, Germany).
Mice were kept under cyclosporine (Sandimmune Cyclosporine, Novartis, Basel,
Switzerland; 10 mg/kg) regimen during the whole treatment. Functional outcome
was measured through gait analysis27 and treadmill assay.28 Both assays were first
tested and validated comparing age-matched, background-matched mice to
dystrophic mice (data not shown). Gait analysis was performed inking the back
paws and letting the mice freely walk along a 1-m-long paper ribbon, confined into a
walled plastic path. More than three runs per time point and ≥ 25 stride length
measurements were analyzed per mouse/time point. Treadmill assay was
performed on 10° uphill-oriented treadmill belt, with 10 m/min starting speed and
1 m/min2 acceleration. Mice were stopped after ≥ 5 consecutive seconds on the
pulse grills.
Flx mice derivation, flx cell isolation and conditional Dll1
knockout. Dll1flx/+ mice were rederived from frozen 2-cell stage embryos,
obtained from Prof. Julian Lewis (Cancer Research UK),29 crossed with Rosa26::
iCreERT2+/− mice, obtained from Prof. Massimiliano Mazzone (VIB, KU Leuven,
Belgium), backcrossed on C57/Bl6 background until obtaining Dll1flx/+;Rosa26::
iCreERT2+/− (flx) mice. Flx MABs were isolated from the skeletal muscle following
the procedures used for wild-type murine MABs, as previously reported.12,14 Flx
SCs were isolated by digesting hind limb skeletal muscles of newborn mice in PBS
supplemented with 0,04% Collagenase V/0,06% Pancreatin (Sigma-Aldrich) while
shaking at 37 °C. After filtration and enzyme blockade, the cell suspension was
FACS-purified by means of SMC2.6 antibody, provided by Prof. So-ichiro Fukada
(University of Osaka, Japan). Flx SCs were cultured on collagen-coated Nunc
plastic with DMEM20% medium supplemented with 1% chicken embryo extract
(Bio-Connect). Intra-arterial injections were performed as mentioned above.
Conditional Dll1 knockout was performed by means of seven intra-peritoneal
injections (every second day) of 3 mg tamoxifen dissolved in 50 μl corn oil (both
reagents by Sigma-Aldrich) into 1-month-old flx females; allele removal was checked
by PCR on 1 ng gDNA 5 days after last injection (primers, Fw
5′-accttctttcgcgtatgcctcaag-3′, Rev, 5′-agagtctgtatggagggcttc-3′). Conditional Dll1
knockout in cells was performed by adding 10 μM 4-OH-tamoxifen (Sigma-Aldrich),
dissolved in ethanol, to the growth medium for 5 days consecutively. Once PCR-
checked for allele removal, Dll1-knockout cells were then used for in vitro
differentiation or in vivo injection.
Statistical analysis. Sample size for in vitro/in vivo experiments was
calculated by means of Sample Size Calculator (http://www.stat.ubc.ca/ ~ rollin/
stats/ssize/index.html; parameters: power,.80; alpha,.05). When applicable, sample
size analysis was based on average values obtained from preliminary optimization/
validation trials. To analyze data pools from methylation propensity and qPCR
assays, one-way ANOVA (to test difference among 42 pools) and unpaired t-test
(to compare two specific pools) were used. Significance was achieved when
Po0.05 in both tests. To analyze data pools of luciferase activity, protein levels,
functional outcome, fiber count, fusion index and Pax7+ nuclei count assays,
Kruskal–Wallis and Mann–Whitney U test were used. Significance was accepted
when Po0.05 was scored in both tests. All statistical tests were performed by
means of Prism software (GraphPad, La Jolla, CA, USA).
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